Does the Senate vote on stem-cell research matter?
By Richard Hayes,
San Francisco Chronicle
| 07. 19. 2006
YES: It's a step toward needed oversight and regulation
After years of rancorous debate, Tuesday's vote by the U.S. Senate on a package of stem-cell research bills suggests that responsible bipartisan action actually may be possible.
Nineteen Republican senators broke with the anti-abortion base of their party and with President Bush, by voting to lift the restrictions imposed five years ago by the president on federal funding for stem-cell research.
On the other side of the aisle, pro-choice Democrats voted to support a companion bill banning the intentional creation and abortion of fetuses in order to use their tissues for experimental purposes. Although no one, as far as anyone knows, has proposed doing this at this time, the vote affirms that liberals and conservatives can agree that some forms of biomedical research are ethically unacceptable and should be prohibited.
Also encouraging was what was left out of the package, notably, any move to authorize federal funding for research cloning, a procedure fraught with risks. At one time, cloning was thought to be necessary for stem-cell therapy to work, but many scientists increasingly believe that this is not the case...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...